Aptamers Market to Reach $12.78 Billion by 2035 at 27.0% CAGR | SomaLogic, NOXXON Pharma, Nitto Denko Avecia Among Key Players

The global aptamers market, valued at USD 0.92 billion in 2025, will reach USD 1.48 billion in 2026 and expand to USD 12.78 billion by 2035, advancing at a compound annual growth rate (CAGR) of 27.0% over the forecast period. This growth reflects accelerating investment across aptamer therapeutics, technologies, and services, as pharmaceutical developers recognize the clinical and commercial potential of these highly specific, single-stranded DNA, RNA, and peptide molecules. With more than USD 1.3 billion deployed in the sector over the past five years and a second FDA-approved aptamer therapy now on the market, the business case for this segment has never been more concrete.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/aptamers-therapeutics-technologies-and-services-market/request-sample.html

Market Overview
Aptamers are short, synthetic single-stranded DNA or RNA molecules, selected through an iterative in-vitro process known as SELEX (Systematic Evolution of Ligands by Exponential enrichment), that bind to specific molecular targets with high affinity and selectivity. They are increasingly positioned as alternatives to monoclonal antibodies across therapeutic, diagnostic, and research applications, offering advantages in chemical stability, manufacturability, and a lower immunogenicity profile. The field gained commercial credibility in December 2004 when the U.S. Food and Drug Administration approved Macugen, the first aptamer-based drug, and the subsequent USD 200 million in annual sales in its first full year of availability demonstrated that aptamers could succeed as a commercial therapeutic modality.

The second FDA approval, granted in August 2023 for Izervay (formerly Zimura), an RNA aptamer developed by Iveric Bio for geographic atrophy secondary to age-related macular degeneration, has substantially refreshed market confidence. Astellas Pharma, which acquired Iveric Bio in July 2023, launched the drug in the United States in September 2023, generating JPY 5.3 billion in revenue during the first nine months of FY 2023. Alongside therapeutic development, COVID-19 spurred a parallel surge in aptamer-based diagnostics, with companies developing rapid-detection tools for SARS-CoV-2. In February 2024, Aptamer Group partnered with Neuro-Bio to develop aptamer-based diagnostic tests capable of detecting Alzheimer's disease biomarkers, broadening the application base further.

More than 50 contract service providers currently hold significant aptamer manufacturing expertise globally, making outsourcing a common and practical approach for therapy developers and diagnostic companies alike. As clinical pipelines advance, contract research and manufacturing organizations serving the aptamers space are set to capture a growing share of the total addressable market.

Key Growth Drivers
FDA Approvals Establishing Commercial Precedent
Two RNA aptamers have now cleared FDA review, creating a regulatory track record that other developers can study and build upon. The commercial performance of Izervay in its first year on the U.S. market confirmed that payors and clinicians will adopt aptamer therapies when the clinical evidence supports efficacy and safety. Developers with therapies in late-stage clinical trials for oncological, cardiovascular, and metabolic disorders are drawing directly on these approval precedents to guide their regulatory strategies.

Over 100 Active Clinical Trials Across Multiple Indications
More than 100 clinical trials are currently evaluating aptamer-based candidates across a range of diseases, including oncological disorders, ophthalmological conditions, and hemophilia. Approximately 46% of aptamer-based therapies remain in pre-clinical development, signaling a full pipeline that will translate into clinical and commercial activity over the next decade. This depth of clinical activity is attracting venture capital, strategic partnerships, and licensing deals that will fuel market revenue through the forecast period.

USD 1.3 Billion in Industry Funding Over Five Years
Investment in aptamer-focused companies has exceeded USD 1.3 billion over the past five years, funding SELEX platform upgrades, AI-enhanced aptamer discovery, and clinical-stage development programs. In July 2023, UK-based Aptamer Group raised £3.6 million to advance its Optimer binders platform. In March 2026, the company conducted an accelerated book build to raise an additional £3.75 million, supported by 27% first-half revenue growth, with proceeds earmarked through 2028 for asset development and AI-integrated discovery workflows.

Technological Innovation in Aptamer Selection and Delivery
Next-generation SELEX methodologies, computational aptamer design, and conjugation strategies that link aptamers with imaging agents, drug payloads, or nanocarriers are making these molecules more versatile. Technologies currently in commercial use span pathogen recognition, cancer biomarker detection, environmental contamination monitoring, and stem cell identification. More than 50 aptamer technologies focused on drug discovery and development applications are now commercially available, with many more in development by both established players and well-funded start-ups.

Rising Demand for Precision Diagnostics and Targeted Therapies
Global disease burden, particularly in chronic and oncological indications, is pushing healthcare systems and pharmaceutical companies toward targeted modalities that reduce off-target effects and development timelines. Aptamers, with their high binding specificity and comparatively straightforward synthesis, fit this need well. The growing use of aptamers in companion diagnostics and liquid biopsy applications further extends their commercial reach beyond pure therapeutics.

Market Segmentation
The aptamers market segments across application area (therapeutics, research, and diagnostics), type of aptamer (DNA, RNA, and peptide), target indication, route of administration, scale of operation, focus area, company size, and geography. Among aptamer types, RNA aptamers currently attract the most development activity, as most pipeline candidates are RNA-based, a pattern consistent with the two FDA approvals granted to date. The therapeutics segment leads by application area, supported by the commercial launches and the depth of the clinical pipeline, though the diagnostics segment is gaining ground rapidly as aptamer-based detection tools earn clinical validation across infectious disease, oncology, and neurodegenerative conditions.

By route of administration, intravitreal delivery holds a meaningful share tied to ophthalmological indications, while intravenous routes serve the broader oncological and hematological pipeline. By focus area, product development commands the largest share of activity today; product commercialization and technology integration are growing as approved drugs scale and platform companies seek to monetize their discovery capabilities. The small-scale operation segment, dominated by discovery-stage researchers and early clinical programs, accounts for a large number of participants, but medium and large-scale operations capture a disproportionate share of revenue as commercial manufacturing requirements grow.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/aptamers-therapeutics-technologies-and-services-market/request-quote.html

Regional Insights
North America holds the largest share of the global aptamers market, with more than 55% of active companies in the aptamer therapeutics space headquartered in the region. The United States is the only market where an approved aptamer drug, Izervay, is currently sold commercially, giving the region a first-mover advantage in generating real-world revenue. The concentration of biopharmaceutical infrastructure, NIH grant funding directed at aptamer research, and a dense contract services ecosystem across the U.S. and Canada reinforces North America's lead position.

Europe represents the second-largest geography, with the United Kingdom emerging as a notable hub for aptamer platform companies. Aptamer Group's repeated capital raises and repeat contracts with major pharmaceutical clients demonstrate that European players are competitive at the commercial services level. The Asia-Pacific region, anchored by Japan, South Korea, and China, is the fastest-growing geography in the forecast, as regional pharmaceutical companies and CROs scale their aptamer manufacturing capacities and governments continue to fund precision medicine initiatives. Japan is already generating commercial revenue through Astellas' marketing of Izervay, contributing directly to Asia-Pacific's rising share.

Competitive Landscape
The aptamers market features more than 170 companies spanning therapy developers, technology platform providers, and contract service organizations. Key players profiled in the Roots Analysis report include Ajinomoto Bio-Pharma Services, BioSpring, CliniSciences, CMIC Group, Halo-Bio RNAi Therapeutics, LGC Biosearch Technologies, NeoNeuro, New England Biolabs, Nitto Denko Avecia, NOXXON Pharma, RIBOMIC, and SomaLogic, among others.

The competitive terrain is bifurcated between a small number of clinical-stage therapy developers with approved or near-approval assets and a larger ecosystem of technology and service providers competing on platform breadth, analytical capability, and manufacturing scale. Start-ups established since 2011 are disproportionately active in technology innovation, using next-generation SELEX, AI-assisted design, and proprietary conjugation chemistry to differentiate their offerings. Intellectual property is a primary competitive battleground; patent filings related to aptamer therapies and technologies have grown at a consistent pace since 2016, with both industry and academic institutions building substantial portfolios. Strategic partnerships and licensing agreements, rather than large-scale M&A, currently define how companies in this space access new indications and geographic markets.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/aptamers-therapeutics-technologies-and-services-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.